Company Description
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer.
The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus.
It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn’s disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma.
Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer’s disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies.
The company was incorporated in 1997 and is headquartered in Pasadena, California.
| Country | United States |
| Founded | 1997 |
| IPO Date | Dec 3, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 250 |
| CEO | Bassil Dahiyat |
Contact Details
Address: 465 North Halstead Street, Suite 200 Pasadena, California 91107 United States | |
| Phone | 626 305 5900 |
| Website | xencor.com |
Stock Details
| Ticker Symbol | XNCR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326732 |
| CUSIP Number | 98401F105 |
| ISIN Number | US98401F1057 |
| Employer ID | 20-1622502 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bassil I. Dahiyat Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
| Bart Jan Cornelissen | Senior Vice President and Chief Financial Officer |
| Dr. John R. Desjarlais Ph.D. | Executive Vice President of Research and Chief Scientific Officer |
| Celia E. Eckert J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Nancy K. Valente M.D. | Senior Advisor |
| Charles Liles | Associate Director and Head of Corporate Communications and Investor Relations |
| Jennifer Sandoz | Senior VIce President of Human Resources |
| Kirk Rosemark RAC | Senior Vice President of Regulatory Affairs and Quality Assurance |
| Eric P. Kowack | Senior Vice President of Program Leadership and Alliance Management |
| Dane Vincent Leone C.F.A. | Executive Vice President and Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 6, 2025 | 10-Q | Quarterly Report |
| Aug 6, 2025 | 8-K | Current Report |
| Jul 31, 2025 | 8-K | Current Report |
| Jul 29, 2025 | SCHEDULE 13G/A | Filing |
| Jun 16, 2025 | 144 | Filing |
| Jun 16, 2025 | 144 | Filing |
| Jun 16, 2025 | 144 | Filing |
| Jun 16, 2025 | 144 | Filing |
| Jun 16, 2025 | 144 | Filing |